NCT05106907View on ClinicalTrials.gov

Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

October 24, 2023

Study Completion Date

October 24, 2024

Conditions
B-cell Malignancy
Interventions
BIOLOGICAL

ThisCART19 cells

0.2-60 x 10\^6 CAR T cells per kg body weight

Trial Locations (1)

Unknown

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Sponsors
All Listed Sponsors
collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

lead

Fundamenta Therapeutics, Ltd.

INDUSTRY

NCT05106907 - Safety and Clinical Activity of ThisCART19 in Patients With r/r Non-Hodgkin's B Cell Lymphoma | Biotech Hunter | Biotech Hunter